Specifically, the OlympiA trial (NCT02032823) has demonstrated that in patients with HER2-negative early BC at high risk and harboring germline BRCA1 or BRCA2 mutations, the use of the adjuvant PARP inhibitor olaparib following local treatment and neoadjuvant or adjuvant chemotherapy resulted in significantly longer overall survival and survival without invasive or metastatic spread compared with the administration of a placebo [118,119]. This evidence concerns the gene BRCA1 and breast cancer.